#Australia #Clinical Trials #Melbourne #Telix Pharmaceuticals #EANM 2026

Telix Pharmaceuticals Highlights at EANM 2026

Telix Pharmaceuticals Limited is set to make a strong impact at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) happening in Vienna, Austria, from October 17th to 21st, 2026. The company will present 20 abstracts that encompass its cutting-edge research and advancements in the field of cancer treatment and diagnostics. This year marks a pivotal moment as 12 abstracts have been selected for prestigious oral presentations, underscoring the significant contributions of Telix to oncology.

Key Studies and Therapies

Among the major highlights is the Phase 3 IPAX BrIGHT trial which investigates TLX101-Tx for recurrent glioblastoma. Additionally, the Phase 3 LUTEON trial examining TLX250-Tx for clear cell renal cell carcinoma (ccRCC) and interim findings from the PTherpan-Lu trial utilizing TLX597-Tx for metastatic androgen pathway modulation-resistant prostate cancer (mAPMR) will be presented. Furthermore, exciting topline data on TLX591-Px (Illuccix) PET imaging in the diagnosis of prostate cancer in Chinese men will also be unveiled.

Dr. David N. Cade, the Chief Medical Officer of Telix, remarked, "Our strong presence at EANM reflects our diverse and mature pipeline, consisting of critical therapeutic studies and precision diagnostics. We anticipate meaningful discussions at our symposium focused on the future of theranostics in urologic oncology."

Symposium and Oral Presentations

Telix will host a sponsored symposium titled "The future doesn't wait: the next era of theranostics in urologic oncology" on October 18, from 1:15 PM to 2:45 PM (CEST) at Hall F2. Key topics will include the evolving role of PSMA-PET imaging in prostate cancer and discussions surrounding next-generation PSMA therapeutics. Moreover, there will be a thorough panel discussion aimed at extending prostate cancer theranostic success to other genitourinary (GU) diseases.

The oral presentations scheduled for October 18th include:
1. ELEGANCE Study: Assessing imaging performance of TLX250-Px in hepatocellular carcinoma and related conditions.
2. HIMIKO Study: Investigating the impact of advanced imaging techniques using TLX591-Px in hepatocellular carcinoma.
3. LUTEON Study: Evaluating the safety and efficacy of TLX250-Tx in advanced and recurrent ccRCC.
4. IPAX BrIGHT Study: Examining TLX101-Tx in patients with recurrent glioblastoma.
5. Further imaging techniques and therapeutic developments from ongoing research will also be discussed.

Innovations in Radiopharmaceuticals

In addition to these presentations, Telix will present innovative advancements in their theranostic pipeline, including groundbreaking studies integrating artificial intelligence (AI) for enhanced imaging precision. Their commercial product, Illuccix—approved for prostate imaging—will be a focal point, and attendees will have the opportunity to engage with the Telix team regarding potential collaborations.

As part of their commitment to fostering future talent in radiology, Telix will support the EANM Sanjiv Sam Gambhir Young Investigator Award.

Attendees are encouraged to visit booth #527 for more insights into Telix’s latest products, including the SENSEI® miniature gamma probe and QDOSE® dosimetry software. This is a prime opportunity to discover cutting-edge solutions developed to improve cancer diagnostics and treatment efficacy.

Overall, Telix Pharmaceuticals’ participation at EANM 2026 signifies a crucial step forward in their quest to optimize cancer therapy through innovative diagnostics and targeted therapeutics, promising enhanced outcomes for patients around the globe.